. Author manuscript; available in PMC: 2020 Mar 1.

Published in final edited form as: J Allergy Clin Immunol. 2018 Jun 30;143(3):844–851. doi: 10.1016/j.jaci.2018.05.021

Table 2:

HIV-specific antibodies, including both broadly neutralizing (bNAbs) and non-neutralizing antibodies (non-NAbs), in clinical trials.

HIV antibody	Target	Function
VRC01, 3BNC117	CD4-binding site (CD4bs)^97-99	bNAbs
10-1037, PGT135	variable region 3 (V3) glycan or high-mannose patch^100,101	bNAbs
A32	CD4-inducible constant regions 1 and 2	Non-NAbs
7B2	gp41 cluster 1	Non-NAbs